PLIVA dd

Greg DeFilippis steps into the CBO role after 20 years of diversified business development experience, most recently as CBO of Halozyme Paulette Gangemi brings more than two decades of expertise leading HR teams in the pharmaceutical and biotechnology industries BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced the appointment of pharmaceutical and medical device expert Greg DeFilippis as Chief Business Officer. Mr. DeFilippis previously served as Senior Vice President, CBO of Halozyme and as CBO at Elektrofi will support business development, collaborations and corporate strategy in the company’s new phase of growth. Elektrofi also announced that it has appointed Paulette Gangemi as Chief Human Resources Officer. Ms. Gangemi will leverage her vast knowledge of Human Resources and leading company-wide transformations in her new role. “I am thrilled to welcome two new executives that each bring extensive knowledge and background in the biotech industry to our senior leadership and growing team,” said Chase Coffman, CEO and Co-Founder of Elektrofi. “Greg’s impressive history in drug delivery and forging new strategic partnerships will be instrumental in the growth of Elektrofi as we prepare for clinical trials and potential partnerships, while I am confident that with Paulette on board, our team will be well equipped to double our headcount of team members dedicated to our mission of redefining the delivery of biologics.” Mr. DeFilippis added, “Elektrofi is at a pivotal time in its growth and is preparing to transition from a preclinical company to a clinical stage company. I am excited to build on the remarkable accomplishments the Elektrofi team have achieved and to ensure that Elektrofi’s business moves in stride with its advancing science.” Mr. DeFilippis most recently served as the Senior Vice President, CBO of Halozyme, where he was responsible for business development, alliance management and project management. Prior to Halozyme, he was the Senior Vice President, Device Business and Alliances at Antares Pharma managing combination drug-device business development, alliance management, product development engineering and project management. Over the course of his career, Mr. DeFilippis has held increasing roles of responsibility in business development, technical operations, supply chain and continuous improvement at biotech and pharmaceutical manufacturing companies including Teva Pharmaceuticals, Barr Laboratories, Pliva, Actavis, and Alpharma. He holds a B.S. in Industrial and Systems Engineering from Virginia Tech and an MBA in Finance from Fairleigh Dickinson University. Ms. Gangemi joins Elektrofi with 20 years of experience leading Human Resources teams in the high-science biopharmaceutical and energy industries. Most recently, she led Employee Relations and Employment Practices at Daiichi Sankyo, Inc., during their transformation into a global oncology company. She was previously the regional head of HR for ThermoFisher Scientific’s Pharmaceutical Services division and also served as Head of HR for the Princeton Plasma Physics Laboratory, a Department of Energy National Lab operated by Princeton University. She holds a master’s degree in Labor and Management Relations from Rutgers University and a B.A. from Green Mountain College in Vermont. Ms. Gangemi added, “Elektrofi has built an incredible team of biologics and drug delivery experts. I look forward to applying my experience to support Elektrofi’s mission to transform the drug delivery paradigm and build a strong company culture in which every member of our team has the tools they need to contribute to that mission.” About Elektrofi Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company is shaping the future of biologics delivery. For more information, visit www.elektrofi.com or follow us on Twitter and LinkedIn. Company ContactJason NorrisCo-Founder, Elektrofimedia@elektrofi.com

WOODCLIFF LAKE, N.J., May 2 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. , today announced that it received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Bayer Pharmaceuticals Corporation's Nimotop(R) (nimodipine) Capsules, 30 mg. The Company will launch its product later this month. Nimotop had annual sales of approximately $29 million for the twelve months ended February 2007, based on IMS sales data. Nimotop (nimodipine) is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). About Barr Pharmaceuticals, Inc. Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 115 generic and 25 proprietary products in the U.S. and more than 1,200 products globally outside of the U.S. Forward-Looking Statements Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and other risks detailed in our SEC filings, including in our Transition Report on Form 10-K/T for the six months ended December 31, 2006. The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law. Barr Pharmaceuticals, Inc. CONTACT: Carol A. Cox of Barr Pharmaceuticals, Inc., +1-201-930-3720,ccox@barrlabs.com Web site: Company News On-Call: /

ZAGREB, Croatia, Oct. 31 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. and its newly acquired subsidiary PLIVA d.d. today announced changes to the Management and Supervisory Boards of PLIVA d.d. The changes resulted from the meeting of PLIVA's Supervisory Board that was held on October 30, 2006 in Zagreb, Croatia. Following the successful closing of Barr's acquisition of PLIVA, Barr and PLIVA are pleased to announce a new combined PLIVA management team with the appointment of three new members to PLIVA's Management Board. PLIVA's Management Board will continue to be led by Zeljko Covic as President and Chief Operating Officer and Ivan Mijatovic will remain as Member and Chief Financial Officer. Joining the Management Board will be Paul M. Bisaro, President and Chief Operating Officer of Barr Pharmaceuticals, Inc., Tim Sawyer, Vice President, Sales for Generic Products in Barr Laboratories, Inc., and Zdravka Knezevic, Executive Director of Global Research and Development in PLIVA, with a mandate through to June 30, 2010. As a result of the combination and change in structure, Mike Urwin has elected to leave the Board but has agreed to stay on for an interim period to help ensure a smooth transition during the integration of both companies. The Board thanks him for his contribution to the company during the last two years. The Supervisory Board also voted to support the Management Board's decision to convene an extraordinary General Assembly for December 19, 2006, where a new Supervisory Board will be elected and PLIVA's Articles of Association will be amended to reflect Barr's legal and regulatory reporting requirements in the United States The current Supervisory Board Members: Massimo Armanini, Franjo Lukovic, Zdenko Adrovic, Branko Jeren, Ivan Vidakovic, Slobodan Vukicevic, Michael Unsworth, Ettore dell' Isola and Ronald Freeman tendered their resignations effective from the date of the extraordinary General Assembly and election of the new Supervisory Board. PLIVA and Barr strongly thank each of them for their contribution to the company during the term of their mandate. The Supervisory Board also discussed PLIVA's preliminary financial results for the nine month period ended September 30, 2006 and will review and approve the final results at its meeting to be held on November 7th, 2006. About Barr Pharmaceuticals, Inc. Barr Pharmaceuticals, Inc., is global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Company markets more than 120 generic and 25 proprietary products in the U.S. and more than 550 products globally. Forward-Looking Statements Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies and products we acquire and implementing our new enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; changes in generally accepted accounting principles; and other risks detailed from time-to-time in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the fiscal year ended June 30, 2006. The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law. Barr Pharmaceuticals, Inc. CONTACT: Carol A. Cox, +1-201-930-3720, ccox@barrlabs.com; Marija Mandic,+385-1-6160-355, marija.mandic@pliva.com Web site: Company News On-Call: